GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » ROC (Joel Greenblatt) %

Nymox Pharmaceutical (Nymox Pharmaceutical) ROC (Joel Greenblatt) %

: -11,266.67% (As of Sep. 2023)
View and export this data going back to 1997. Start your Free Trial

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Nymox Pharmaceutical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -11,266.67%.

The historical rank and industry rank for Nymox Pharmaceutical's ROC (Joel Greenblatt) % or its related term are showing as below:

NYMXF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -661250   Med: -33524.24   Max: -1454.62
Current: -1454.62

During the past 13 years, Nymox Pharmaceutical's highest ROC (Joel Greenblatt) % was -1454.62%. The lowest was -661250.00%. And the median was -33524.24%.

NYMXF's ROC (Joel Greenblatt) % is ranked worse than
72.36% of 1469 companies
in the Biotechnology industry
Industry Median: -339.22 vs NYMXF: -1454.62

Nymox Pharmaceutical's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 65.10% per year.


Nymox Pharmaceutical ROC (Joel Greenblatt) % Historical Data

The historical data trend for Nymox Pharmaceutical's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROC (Joel Greenblatt) %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32,048.48 -13,600.00 -3,834.75 -2,920.09 -2,276.31

Nymox Pharmaceutical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROC (Joel Greenblatt) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,282.85 3,618.09 -3,929.08 -5,146.20 -11,266.67

Competitive Comparison

For the Biotechnology subindustry, Nymox Pharmaceutical's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical ROC (Joel Greenblatt) % Distribution

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's ROC (Joel Greenblatt) % falls into.



Nymox Pharmaceutical ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.072) - (2.343 + 0 + 0)
=-2.271

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.571) - (2.56 + 0 + 0)
=-1.989

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Nymox Pharmaceutical for the quarter that ended in Sep. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-4.056/( ( (0.057 + max(-2.271, 0)) + (0.015 + max(-1.989, 0)) )/ 2 )
=-4.056/( ( 0.057 + 0.015 )/ 2 )
=-4.056/0.036
=-11,266.67 %

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nymox Pharmaceutical  (OTCPK:NYMXF) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Nymox Pharmaceutical ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

Nymox Delisting from NASDAQ

By Marketwired 07-05-2023

NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference

By GlobeNewswire GlobeNewswire 11-15-2021

NYMOX Provides Shareholder Update

By Marketwired Marketwired 09-10-2021

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-12-2022

NYMOX Update

By Marketwired 07-07-2023

NYMOX Appeals Deficiency Letter

By GlobeNewswire GlobeNewswire 01-06-2023

Nymox Announces $5 Million Registered Direct Offering

By GuruFocusNews GuruFocusNews 03-18-2022

NYMOX Receives Deficiency Letter from NASDAQ

By PurpleRose PurpleRose 07-14-2022